Key Takeaways
- Margin beat, revenue trimmed: Standalone EBITDA margin improved ~203 bps YoY to 22.89%, but full-year revenue growth guidance was cut to ~9-10% from 10-11% on export headwinds.
- Domestic formulation is the engine: IPCA outpaced IPM across both acute (12% vs 7%) and chronic (17% vs 10%) segments, gaining ~10 bps of market share in the quarter.
- Unichem integration is on track but early: EBITDA margin improved to 14.35% in Q2, procurement synergies are realized, and API cost reductions of 25-30% are validated, yet API sourcing from IPCA and market extensions are still 5-12 months away.
- U.S. re-entry is a 3-5 year story: Three products have shipped but primary sales were knocked out in consolidation; sales recognition begins Q3, with ~6 launches this year and a similar cadence next year, all building from a base of zero.
- What to watch next quarter: Whether U.S. sales actually begin reflecting in Q3, the pace of Unichem's own 5-6 new molecule launches, and any stabilization in South Africa and UK tender businesses.
Domestic Formulation: The Standout Performer
- Broad-based outperformance: IPCA grew acute therapies at 12% versus the IPM's 7%, and chronic at 17% versus the market's 10%, a gap management attributes to field force execution and brand strength.
- Market share gains compounding: Overall market share improved ~11 bps YoY, with Q2 alone adding ~10 bps; the CTD-T brand entered the top 300 brands with an 88% rank gain.
- Steady growth regardless of industry cycle: When the industry grew 15-20%, IPCA grew 11-12%; now that the industry has slowed to 6%, IPCA is still growing at 11-12%, suggesting a structural rather than cyclical driver.
- India business guidance reaffirmed: 11-12% growth for FY25, with no sign of the October IQVIA slowdown to 6% affecting internal numbers.
Margin Walk & Profitability
- Standalone margin expansion: EBITDA margin reached 22.89%, up ~203 bps YoY, driven by better product mix, lower input costs, and reduced manufacturing and other overhead. Full-year standalone margin is now expected around 22%, up from the earlier 21% guideline.
- Consolidated margin improvement: EBITDA margin improved ~146 bps YoY to 19.10%, despite Unichem consolidation for the full six months versus only one month and a few days last year. Full-year consolidated margins will be better than earlier guidelines.
- Productivity gains alongside headcount addition: Overall productivity improved from 4.36 lakh to 4.62 lakh in the first half, even as the company added people.
- Other expenses run rate stable: Management indicated the Q1 and Q2 consolidated other expenses run rate will continue, with no exceptional expenses expected.
Harish Kamath: "Consolidated is more important than stand-alone. So as far as generic business is concerned, better let us go by consolidated guidelines."
Unichem Integration: Early Progress, Long Road
- Margin trajectory improving: Unichem EBITDA margin moved from 12.52% in Q1 to 14.35% in Q2, and is expected to remain at 14-15% for the rest of the year. Management's initial calculations point to around INR 200 crores of EBITDA from the second year onwards.
- Cost synergies materializing now: Procurement benefits from IPCA's lower pricing have already been extended to Unichem. For ~6 products, manufacturing cost has been reduced by 25-30% and validations are complete.
- Revenue synergies are still pending: Unichem sourcing APIs from IPCA has not started and may take 5-6 months, so nothing material will happen in the current year. Extending IPCA's larger product range to Unichem's other markets will take another ~1 year due to regulatory processes and data generation.
- U.S. consolidation complete: Bayshore's U.S. business has been transferred to Unichem, and the entire U.S. business will now run under one umbrella to avoid duplication of marketing and administrative setup.
- Biotech R&D stopped: Unichem's biotech R&D work has been completely discontinued, removing a cost drag.
A.K. Jain: "So in current year, practically nothing of that nature will happen."
U.S. Re-entry: Building from Zero
- The relaunch has begun but sales are not yet recognized: Three products shipped to Unichem have landed in the U.S., but primary sales were knocked off in consolidation because the products have not moved to the market yet. Sales recognition will start reflecting from Q3 onwards.
- Launch cadence taking shape: IPCA will launch ~6 products in the U.S. this year (3 already sent, 3 in the pipeline), with a similar number expected next financial year. Unichem itself is launching 5-6 of its own new molecules in the U.S. market this year.
- Pricing better than a decade ago: IPCA historically held very large market share in these products. After exiting, prices increased, then moderated, but remain better than 10 years back. Gaining market share back will take time.
- Long-term growth story: IPCA's U.S. sales are currently zero, so management expects very good growth in the next 3-5 years as products are sold. Cross-selling Unichem products into ROW, Europe, Australia, New Zealand, and Canada adds a second leg.
Harish Kamath: "In these products, we were having a very big market share. The moment we went out, the prices increased. They have moderated, of course, subsequently. But still it is now better than what it was 10 years back."
Export Headwinds & Segment Weakness
- API export decline drags the segment: Overall API declined ~5%, with domestic API recovering at ~14% growth but API exports continuing to decline.
- Branded formulation muted on currency: First-half branded formulation growth was minus 2%, largely due to currency fluctuations, especially the ruble moving from 80 to over 95.
- South Africa tender losses: Certain tender products were lost in South Africa, and last year's strong second half from that market looks difficult to repeat.
- UK market challenges: The UK market also faces headwinds, adding to the export pressure.
- Guidance reflects caution: Full-year revenue growth guidance was trimmed to ~9-10% from 10-11%, with standalone generic growth around 8%. Management explicitly called the guidance "muted" and left room for upside if conditions improve.
Harish Kamath: "There are challenges... Considering all that, we are giving a muted guidance. If the situation improves, we may do better than what we are committing."
Subsidiaries & Other Businesses
- Institutional business spike is temporary: Institutional business grew ~85% because injectables were not available in the same period last year. This will fluctuate between INR 300-400 crores annually going forward.
- Trophic Wellness steady: The nutraceutical subsidiary is doing reasonably well with 10-12% top line and 15-20% bottom line growth.
- Onyx Scientific facing demand softness: The UK-based CRAMS business is steady but has an issue with discretionary spending coming down in the market.
- Unichem's non-U.S. performance mixed: U.S. business grew ~12-12.5%, but Brazil declined; contract manufacturing did well. Pricing decline was contained at ~1-1.5%.
- All plants now cleared: All three IPCA units, including Piparia, have received approvals with no pending issues anywhere, removing a regulatory overhang.
R&D and Pipeline Investment
- R&D spend to step up meaningfully: Current R&D spend is ~3-3.5% of revenue. After the biotech plant commissions at the end of this financial year, R&D cost may rise to ~4.25-4.5% next financial year.
- Unichem capacity underutilized: Goa Unit 2, the larger facility, is at only ~20% utilization, leaving significant operating leverage available as U.S. business and other markets expand.
- Sales force productivity timeline: Additional people added will become productive division-wise over 2-3 years, with some divisions like cardiac expected to ramp faster.
A.K. Jain: "But our initial calculations, where we were talking that on second year onwards, we should be able to get around INR200 crores kind of EBITDA margin."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone EBITDA margin | Around 22% (raised from 21%) | FY25 full year |
| Consolidated revenue growth | ~9% (cut from 10-11%) | FY25 full year |
| India formulation growth | 11-12% | FY25 full year |
| Unichem revenue | INR 1,850-1,900 crores | FY25 full year |
| Unichem EBITDA margin | 14-15% | Remaining FY25 quarters |
| Unichem product launches | 4-5 formulation products per year | Ongoing annual cadence |
| U.S. product launches (IPCA) | ~6 products | FY25 (3 shipped, 3 in pipeline) |
| U.S. product launches (Unichem own) | 5-6 new molecules | FY25 |
| U.S. sales recognition start | From Q3 onwards | FY25 |
| R&D spend step-up | To ~4.25-4.5% of revenue | FY26 (post biotech plant commissioning) |
| Unichem API sourcing from IPCA | To begin | ~5-6 months from now |
| Unichem market extensions | Larger product range to other markets | ~1 year (regulatory process) |
| Unichem second-year EBITDA | Around INR 200 crores | From second year onwards |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Consolidated revenue growth guidance (FY25) | ~9%, revised from earlier 10%–11% |
| Standalone EBITDA margin | 22.89%, vs 20.86% in Q2 FY24, improvement of ~2.03 ppt |
| Consolidated EBITDA margin | 19.10%, vs 17.64% in Q2 FY24, improvement of ~1.46 ppt |
| Standalone EBITDA margin guidance (FY25) | ~22%, revised from earlier ~21% |
| Domestic formulation growth | 11% for the quarter |
| IPM growth (IQVIA) | ~8%; IPCA delivered ~14% growth |
| Acute segment growth | ~12% for IPCA, vs market growth of ~7% |
| Chronic segment growth | ~17% for IPCA, vs market growth of ~10% |
| Market share | 2.14% in Q2 FY25, vs 2.04% in Q2 FY24, improvement of ~10 bps |
| Brands in top 300 IPM brands | 6 brands; CTD-T entered at rank 193 |
| Generic business growth | ~15% overall for the quarter |
| Institutional business growth | ~85% for the quarter |
| Overall API business revenue | ₹319 cr, vs ₹335 cr in Q2 FY24, decline of ~5% |
| Domestic API growth | ~14% for the quarter |
| Unichem revenue guidance (FY25) | ₹1,850–₹1,900 cr, revised from earlier ~₹2,000 cr |
| Unichem Q2 EBITDA margin | 14.35%, improved from 12.52% in Q1 FY25; expected 14%–15% for remaining period |
| Unichem Q2 revenue growth | ~11%; consolidated sales improvement ~9.4% |
| Unichem U.S. business growth | ~12%–12.5% |
| Unichem pricing decline | ~1%–1.5% |
| Unichem Unit 1 Goa and Ghaziabad capacity utilization | ~70%–80% |
| Unichem Unit 2 Goa capacity utilization | ~20% |
| Unichem Bambi plant capacity utilization | ~30%–35% |
| IPCA goods shipped to U.S. (up to September) | ~₹30 cr worth; ~₹1–₹1.5 cr sales recorded, rest in stock |
| Branded formulation growth (H1 FY25) | -2% |
| R&D spend (consolidated) | ~3% of turnover; may rise to ~4.25%–4.5% next FY after biotech plant commissioning |
| U.S. product launches planned (FY25) | ~6 products; 3 already shipped, 3 in pipeline |
| Unichem U.S. product launches planned (FY25) | 5–6 new molecules |
| Generic business growth guidance (FY25, consolidated) | 10%–12%; H1 growth was 2% |
| Generic business growth guidance (FY25, standalone IPCA) | ~8% |
| India business growth guidance (FY25) | 11%–12% |
| Institutional business annual revenue range | ₹300–₹400 cr going forward |
| Sales force | ~7,000 medical reps |
| Productivity per rep (H1 FY25) | ~₹4.62 lakh, vs ₹4.36 lakh in H1 FY24 |
| Historical U.S. total business (2013–2015) | ~₹400 cr, including ~₹150–₹160 cr API business |
| Subsidiaries revenue (excluding Unichem) | ~₹80 cr |
| Trophic Wellness top line growth | ~10%–12%; bottom line growth ~15%–20% |